Nanobiotix

Curadigm Sas

Centre National De La Recherche Scientifique

Universitë De Bordeaux

Curadigm

Matthieu Germain

Laurent Levy

Marie-Edith Meyre

Agnes Pottier

Agnès Pottier

Audrey Darmon

Laurence Poul

Celine Berjaud

Agnés Pottier

Julie Marill

Cyril Lorenzato

Chrit Moonen

Pierre Smirnov

Annabelle Rouet

Marion Paolini

Corinne Devaux

Marie-edith Meyre

Céline Berjaud

The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.

Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.

Pharmaceutical composition, preparation and uses thereof

The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.

Pharmaceutical compositions, preparation and uses thereof

The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody. According to the methods of the invention, administering the biocompatible nanoparticle comprising oligomers of albumin after administering the pharmaceutical compound maintains or increases the therapeutic benefit and reduces toxicity of the pharmaceutical compound when compared to the therapeutic benefit and toxicity induced by administering the pharmaceutical compound alone.

Methods of treatment utilizing biocompatible nanoparticles and therapeutic agents

The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis

The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein: i) the nanoparticles and/or nanoparticles of said aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticles and nanoparticle aggregates being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 sof the gel comprising the nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa&#xb7;s and about 1000 Pa&#xb7;s when measured between 20&#xb0; C. and 37&#xb0; C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using an X-ray imaging equipment.

Compositions and methods for use in medical diagnosis

The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticles aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticles aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticles aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticles aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.

Pharmaceutical composition comprising nanoparticles, preparation and uses thereof

The invention pertains to a method of monitoring the membrane permeabilization of a liposome and the incidental release of a compound of interest. The method utilizes liposomes comprising a thermosensitive lipidic membrane encapsulating the product of interest and superparamagnetic nanoparticles having the electrostatic surface charge below &#x2212;20 mV or above +20 mV when measured in an aqueous medium at physiological pH. In one embodiment, the method comprises the steps of: a) measuring relaxation time (T2*); b) heating the liposome at Tm or above Tm; c) measuring T2* after step b); d) obtaining the transverse relaxivity (r) values from the T2* values obtained from step a) and step c); and e) determining the ratio of rbefore and after the heating step b). A ratio above 1.5 indicates the liposome membrane permeabilization and the incidental release of the product of interest.

Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles

The invention pertains to thermosensitive liposomes encapsulating nanoparticles. In certain embodiments, the thermosensitive liposomes of the invention disrupt when heated at gel-to-liquid crystalline phase transition temperature (Tm) or above Tm, wherein the liposome comprises a thermosensitive lipidic membrane encapsulating nanoparticles. The nanoparticles used in the invention comprise an inorganic core the largest dimension of which is less than about 100 nm that is fully coated with an agent responsible for the presence of an electrostatic charge below &#x2212;20 mV or above +20 mV at the surface of the nanoparticle, the electrostatic charge being determined by zeta potential measurements in an aqueous medium between pH 6 and 8, for a concentration of nanoparticles in suspension in the aqueous medium varying between 0.2 and 8 g/L. The invention also relates to pharmaceutical and diagnostic compositions comprising the thermosensitive liposomes as well as to their uses.

Nanoparticles delivery systems, preparation and uses thereof

The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X-Rays, &#x3b3;-Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same.

Growing community of inventors

Champigny sur Marne, France

Matthieu Germain